What does gonadorelin do?

Gonadorelin is a synthetic version of GnRH, also called gonadotropin-releasing hormone. The source describes it as a 10-amino-acid peptide that signals the pituitary to release LH and FSH, with established diagnostic use and historical use for ovulation induction. Off-label TRT-support claims are noted by the source but are not presented as proven by large randomized trials.

How does gonadorelin work?

It acts at GnRH receptors on anterior-pituitary gonadotroph cells. The reported signaling pathway involves phospholipase C, calcium mobilization, and protein kinase C, followed by LH and FSH synthesis and release. Pulsatile exposure is central to the source description: pulse-like delivery can stimulate the axis, while sustained exposure can desensitize receptors and suppress LH and FSH.

Is gonadorelin FDA approved?

The source lists FDA Approved status but also states that the previously approved diagnostic product Factrel has been discontinued and that no FDA-approved gonadorelin product is currently marketed in the US. It further reports availability only as 503A-compounded.

What side effects are reported for gonadorelin?

Reported effects in the source include injection site reactions, headache, flushing, nausea, risk of multiple births, possible worsening of hormone-dependent cancers, and long-term bone density decrease. Individual risk cannot be determined from this draft.

What dose does the source report for gonadorelin?

The source reports a community common dose of 100-500 mcg 2-3x weekly, with a range of 50-500 mcg per dose, and administration by IV, subcutaneous route, or pulsatile pump. It also reports a research/labeling row of 100 mcg IV/SC for diagnostic testing. These entries preserve source-reported values and are not treatment instructions.

Hormonal FDA Approved - approved for specific uses

Gonadorelin

Also known as: GnRH, LHRH, Factrel

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

Synthetic GnRH peptide where pulsatile timing is central to LH and FSH stimulation.

Status

FDA Approved

Evidence level: human clinical evidence

Typical dose

100–500mcg

Researched for

Hormone stimulation, fertility, TRT support

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

FDA approved - FDA-approved for specific uses with established human evidence

Use the tools

In plain language

Synthetic GnRH with the sequence pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2.
Source lists FDA Approved status, with the nuance that the former Factrel diagnostic product is discontinued and no FDA-approved gonadorelin product is currently marketed in the US.
Reported typical community dose is 100-500 mcg 2-3x weekly; administration routes listed are IV, , or pulsatile pump.
Researched or discussed for hormone stimulation, fertility, and TRT support, with TRT-adjunct use described as less strongly trial-backed than established diagnostic biology.

How it's thought to work

Gonadorelin is described as a synthetic GnRH that engages GnRH receptors on gonadotroph cells in the anterior pituitary. The source reports signaling through phospholipase C with calcium and protein kinase C involvement, leading to LH and FSH production and release. Those gonadotropins then influence ovarian or testicular function, including sex-steroid production and gamete development. The source emphasizes pattern of exposure: pulsatile delivery, similar to endogenous GnRH rhythms of about 60 to 120 minutes, supports stimulation, whereas continuous exposure can desensitize and downregulate the receptor and reduce LH and FSH output.

What the research shows

Where the research stands

The source frames gonadorelin as an established GnRH molecule rather than an experimental novelty. Diagnostic GnRH stimulation testing is described as established, and pulsatile pump administration is reported in hypogonadotropic hypogonadism, delayed puberty, and fertility induction. Because the is short-lived, the source notes that historical clinical use depended on pumps or frequent administration, while longer-acting GnRH agonists later displaced some uses. The source also describes off-label TRT-adjunct use as common in some clinic and online settings, but supported mainly by mechanism, small-scale experience, or anecdote rather than large randomized comparisons showing superiority over HCG.

What it shows

✓ Human clinical evidence

FDA-approved for specific uses with established human evidence

△ Limitations

Use only according to approved labeling and qualified medical guidance.

Bottom line: Previously FDA approved as Factrel for diagnostic use; that brand is discontinued, no FDA-approved gonadorelin product is currently marketed in the US, and the source reports availability only as 503A-compounded. FDA Approved; previously approved Factrel diagnostic product is discontinued, and no FDA-approved gonadorelin product is currently marketed in the US per source.

Typical dosing

CommunityCommunity dataset

100–500 mcg

2-3x weekly

50 mcgfull range seen500 mcg

Community-reported use is described for TRT support and often alongside HCG protocols. This row is not medical advice and is not presented as validated clinical dosing. · IV, subcutaneous, or pulsatile pump

Research dosing

Indication-specificApproved for specific uses - study doses are indication-specific

Doses observed in studies

100 mcg IV/SC for diagnostic testing

FDA Approved Labeling - Prescribed dose

Use only according to approved labeling and qualified medical guidance.

Duration: Single dose (diagnostic) or ongoing (therapeutic)
Administration: IV, subcutaneous, or pulsatile pump

Timing & administration

Best time to take

Morning or as clinically directed

As prescribed, often pulsatile

Food recommendation

With or without food

Why this timing?

The source links gonadorelin use to protocol-specific timing and emphasizes that the delivery pattern changes the biological effect. Pulsatile exposure is associated with LH and FSH stimulation, while continuous exposure can reduce receptor responsiveness and suppress those gonadotropins.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Injection site reactions
Headache
Flushing
Nausea
Risk of multiple births
May worsen hormone-dependent cancers
Long-term bone density decrease

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

Sequence

pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Gonadorelin

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Gonadorelin

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions